MR quantification of the washout changes in breast tumors under preoperative chemotherapy: Feasibility and preliminary results

American Journal of Roentgenology

Volumn 184, Issue 5, 2005, Pages 1499-1504

  El Khoury, Carl ^a   Servois, Vincent ^a   Thibault, Fabienne ^a   Tardivon, Anne ^a   Ollivier, Lilianne ^a   Meunier, Martine ^a   Allonier, Caroline ^a   Neuenschwander, Sylvia ^a  

^a INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; BREAST BIOPSY; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; FEASIBILITY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ENHANCEMENT; INVASIVE CARCINOMA; LUNG CARCINOMA; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAMETRIC TEST; PARTIAL MASTECTOMY; PATHOLOGICAL ANATOMY; PREOPERATIVE CARE; PRIORITY JOURNAL; REPRODUCIBILITY; RETROSPECTIVE STUDY; STUDENT T TEST; ARTICLE; IMAGE PROCESSING; METHODOLOGY; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEASIBILITY STUDIES; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 19844379970     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/ajr.184.5.01841499     Document Type: Conference Paper

References (24)

1. Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990;82:1539-1545
2. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001:96-102
3. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19:4224-4237
4. Drew PJ, Kerin MJ, Mahapatra T, et al. Evaluation of response to neoadjuvant chemoradiotherapy for locally advanced breast cancer with dynamic contrast-enhanced MRJ of the breast. Eur J Surg Oncol 2001;27:617-620
5. Balu-Maestro C, Chapellier C, Bleuse A, Chanalet I, Chauvel C, Largillier R. Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. Breast Cancer Res Treat 2002;72:145-152
6. Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol 1999;17:110-119
7. Delille JP, Slanetz PJ, Yeh ED, Kopans DB, Garrido L. Breast cancer: regional blood flow and blood volume measured with magnetic susceptibility-based MR imaging-initial results. Radiology 2002;223:558-565
8. Hayes C, Padhani AR, Leach MO. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 2002;15:154-163
9. Tsuboi N, Ogawa Y, Inomata T, et al. Changes in the findings of dynamic MRI by preoperative CAF chemotherapy for patients with breast cancer of stage II and III: pathologic correlation. Oncol Rep 1999;6:727-732
10. Rieber A, Zeitler H, Rosenthal H, et al. MRI of breast cancer: influence of chemotherapy on sensitivity. Br J Radiol 1997;70:452-458
11. Kuhl CK, Mielcareck P, Klaschik S, et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 1999;211:101-110
12. Buadu LD, Murakami J, Murayama S, et al. Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology 1996;200:639-649
13. Sherif H, Mahfouz AE, Oellinger H, et al. Peripheral washout sign on contrast-enhanced MR images of the breast. Radiology 1997;205:209-213
14. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989;45:255-268
15. Vincent-Salomon A, Carton M, Freneaux P, et al. ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy. Eur J Cancer 2000;36:586-591
16. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995;180:297-306
17. Kinkel K, Helbich TH, Esserman LJ, et al. Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability. AJR 2000;175:35-43
18. Schwickert HC, Stiskal M, Roberts TP, et al. Contrast-enhanced MR imaging assessment of tumor capillary permeability: effect of irradiation on delivery of chemotherapy. Radiology 1996;198:893-898
19. Leunig M, Yuan F, Menger MD, et al. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res 1992;52:6553-6560
20. Boucher Y, Brekken C, Netti PA, Baxter LT, Jain RK. Intratumoral infusion of fluid: estimation of hydraulic conductivity and implications for the delivery of therapeutic agents. BrJ Cancer 1998;78:1442-1448
21. Mussurakis S, Buckley DL, Coady AM, Turnbull LW, Horsman A. Observer variability in the interpretation of contrast enhanced MRI of the breast. Br J Radiol 1996;69:1009-1016
22. Makris A, Powles TJ, Kakolyris S, Dowsett M, Ashley SE, Harris AL. Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. Cancer 1999;85:1996-2000
23. Marson LP, Kurian KM, Miller WR, Dixon JM. The effect of tamoxifen on breast tumor vascularity. Breast Cancer Res Treat 2001;66:9-15
24. Blackwell KL, Haroon ZA, Shan S, et al. Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. Clin Cancer Res 2000;6:4359-4364